▲ +28.74% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Passage Bio in the last 3 months. The average price target is $25.53, with a high forecast of $35.00 and a low forecast of $2.21. The average price target represents a 28.74% upside from the last price of $19.83.
The current consensus among 8 polled investment analysts is to buy stock in Passage Bio.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (Ã-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin for the treatment of FTD caused by a deficiency of progranulin; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase, for infantile Krabbe disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.